Adam C. Kennedy

Dr. Adam C. Kennedy serves as a Postdoctoral Research Fellow at the ARC Development of Advanced Radiochemical Technologies (DART) Industrial Transformation Training Centre within the School of Chemistry at Monash University. His research focuses on developing radiochemical technologies through peptide engineering and metal complexation for therapeutic applications.

Education

• PhD, Monash University, 2023

Research Expertise

Dr. Kennedy's work spans critical domains in medicinal radiochemistry:

• Design of peptides and peptidomimetics for radiochemical applications
• Optimization of bioconjugation strategies for bifunctional chelators
• Development of novel metal-peptide complexes for theranostics

His research directly supports United Nations Sustainable Development Goal 3 (Good Health and Well-being) through innovations in targeted radiotherapy and diagnostic imaging agents.

Publication Profile

His scholarly output demonstrates interdisciplinary convergence between peptide science and radiochemistry. The 2020 review on α-conotoxin peptidomimetics established structure-activity relationships for pain management, while the 2018 spectroscopy study provided fundamental insights into ion solvation behavior. These works reflect his dual focus on therapeutic development and molecular characterization techniques.

Honors and Recognition

• No scientific awards documented in current sources

Research Leadership

As a core researcher in the ARC DART Centre, Dr. Kennedy contributes to this Australian Research Council-funded initiative focused on advancing radiotheranostic technologies and training next-generation radiochemists. No student advisement activities are currently documented.

Collaborative Framework

He operates within Monash University's radiochemistry ecosystem through the ARC DART Centre, collaborating with multidisciplinary teams on peptide-based radiopharmaceutical development and participating in the broader network of the School of Chemistry's research infrastructure.